|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Alaa Ahmad,
Associate Director, Clinical Pharmacology Modelling & Simulation Bristol-Myers Squibb Dr. Alaa Ahmad is currently an Associate Director of Clinical Pharmacology, Modeling and Simulation in Discovery Medicine and Clinical Pharmacology (DMCP) at
Bristol-Myers Squibb, Princeton, NJ. From 2005-2009, Dr. Ahmad worked at Vertex Pharmaceuticals Inc., in Cambridge, MA, in different roles, last of which was an Associate Director of Clinical Pharmacology. Dr. Ahmad holds a Doctor of Philosophy Degree in Pharmaceutical Sciences from Virginia Commonwealth University, Richmond, VA and a Bachelor of Science Degree in Pharmacy from the University of Jordan, Amman, Jordan.
Appearing: Day One, Wednesday 20 October 2010 1.30pm Quantitative Knowledge Integration to Inform Dose Selection in Early Clinical Development
- Quantitative Knowledge Integration in Drug Development
- Dose Selection/Design for Non-Oncology First-In-Human Studies
- Dose Selection for Proof-of-Concept and Phase 2 a studies
- Leveraging Prior Clinical Experience to Inform Dose Selection for Phase 2a
Alaa Ahmad, Associate Director, Clinical Pharmacology Modelling & Simulation,
Bristol-Myers Squibb |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
